(30 days)
Not Found
No
The description focuses on the physical properties and performance of the microspheres for embolization, with no mention of AI or ML in the device description, intended use, or performance studies.
Yes
The device is used for embolization of hypervascularized tumors and arteriovenous malformations, which is a therapeutic intervention aimed at treating medical conditions.
No
The device is described as an embolization agent used for treating hypervascularized tumors and arteriovenous malformations, which is a therapeutic rather than a diagnostic function.
No
The device description clearly states that the device is composed of physical microspheres, which are a hardware component. The performance studies also focus on the physical properties and behavior of these microspheres.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD Definition: In vitro diagnostics are tests performed on samples taken from the human body, such as blood, urine, or tissue, to detect diseases, conditions, or infections. They are used to provide information for diagnosis, monitoring, or screening.
- Device Description and Intended Use: The description of QuadraSphere Microspheres clearly states they are used for embolization of hypervascularized tumors and arteriovenous malformations. This is a therapeutic procedure performed within the body to block blood vessels.
- Lack of Diagnostic Testing: There is no mention of this device being used to analyze samples from the body or provide diagnostic information. Its function is purely mechanical (blocking blood flow).
Therefore, QuadraSphere Microspheres are a therapeutic medical device, not an in vitro diagnostic device.
N/A
Intended Use / Indications for Use
QuadraSphere Microspheres are indicated for embolization of hypervascularized tumors including hepatoma, and peripheral arteriovenous malformations.
Product codes (comma separated list FDA assigned to the subject device)
KRD, HCG
Device Description
QuadraSphere Microspheres are sterile, biocompatible, hydrophilic, nonresorbable, expandable, acrylic copolymer microspheres. QuadraSphere Microspheres are packaged in a vial containing 25 mg of dry microspheres. The expansion rate is dependent on ionic concentration. When in contact with blood, non-ionic contrast media, or normal saline (NaCl 0.9%), QuadraSphere Microspheres expand to approximately 4 times their dry state diameter; equal to 64x volume.
They are available in a range of sizes.
- Spherical shape with consistent cross sectional diameter after reconstitution with aqueous-based solutions such as contrast media and 0.9% saline solution for predictable flow directed level of occlusion in the vasculature.
- Rapidly absorb contrast media and 0.9% saline solution.
- Conform to vessel lumen, providing more surface contact with vessel intima.
- Expand up to four times the stated dry diameter when hydrated with non-ionic aqueous solutions, resulting in an increase in surface area contact for a more complete vessel occlusion.
The principles of operation for the QuadraSphere Microspheres are the same as the predicate device K153102. QuadraSphere Microspheres are permanent implantable devices and are designed for controlled, targeted embolization. The device is provided dry (in a vial) and must be rehydrated before use. The microspheres are injected into the target vessel with an intravascular catheter(s) to selectively occlude blood vessels. Contrast enhancement using commercially available ionic or non-ionic contrast media allows the embolization procedure to be monitored using fluoroscopy. The embolization agents are intended for single use and are provided sterile.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
fluoroscopy
Anatomical Site
vessels related to hypervascularized tumors including hepatoma, and peripheral arteriovenous malformations
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Safety & Performance Tests
No performance standards applicable to this device have been adopted under Section 514 of the Act. However, vascular embolization devices are subject to the special controls specified in "Guidance for Industry and FDA Staff - Class II Special Controls Guidance Document: Vascular and Neurovascular Embolization Devices," issued on December 29, 2004.
Biocompatibility assessment was performed in accordance with ISO 10993-1 for permanent implants in contact with blood for the predicate device and are being adopted for this subject device based upon the fact that both devices are made from the same materials using the same processes with now the inclusion of an additional size offering.
In-vitro and in-vivo (animal study) design verification and validation testing demonstrates that the BioSphere Medical QuadraSphere Microspheres 20 to 40µm fulfill design and performance specifications. Performance testing of the subject device was conducted based on the requirements of design input and output requirements as below:
- Macroscopic appearance of the powder
- Microscopic examination of the microspheres
- Swelling in Hexabrix of the microspheres
- Humidity of the microspheres
- Bacterial endotoxins
- Catheter compatibility
- Animal testing
The results of the testing demonstrated that the subject BioSphere Medical QuadraSphere Microspheres 20 to 40 µm met the pre-determined acceptance criteria applicable to the size requirements and performance of the device.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 870.3300 Vascular embolization device.
(a)
Identification. A vascular embolization device is an intravascular implant intended to control hemorrhaging due to aneurysms, certain types of tumors (e.g., nephroma, hepatoma, uterine fibroids), and arteriovenous malformations. This does not include cyanoacrylates and other embolic agents, which act by polymerization or precipitation. Embolization devices used in neurovascular applications are also not included in this classification, see § 882.5950 of this chapter.(b)
Classification. Class II (special controls.) The special control for this device is the FDA guidance document entitled “Class II Special Controls Guidance Document: Vascular and Neurovascular Embolization Devices.” For availability of this guidance document, see § 870.1(e).
0
Image /page/0/Picture/2 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is a stylized image of three human profiles facing to the right, with flowing lines representing hair or movement.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
September 6, 2017
Biosphere Medical, S.A. Lionel Ngando Regulatory Affairs Specialist Parc des nations - Paris Nord 2 383 Rue de la Belle Etoile 95700 Roissy en France, France
Re: K172372
Trade/Device Name: QuadraSphere Microspheres Regulation Number: 21 CFR 870.3300 Regulation Name: Vascular Embolization Device Regulatory Class: Class II Product Code: KRD, HCG Dated: August 2, 2017 Received: August 7, 2017
Dear Lionel Ngando:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR
1
Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical devicerelated adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education (DICE) at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education (DICE) at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely.
Joyce M. Whang -S
for
Benjamin R. Fisher, Ph.D. Director Division of Reproductive, Gastro-Renal, and Urological Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
2
Image /page/2/Picture/1 description: The image contains the logo for BioSphere Medical. The logo consists of a blue circle with white curved lines inside, followed by the text "BioSphere" in a larger, bold font. Below "BioSphere" is the word "Medical" in a smaller font.
Section 4 Indications for Use Statement
| DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration | Form Approved: OMB No. 0910-0120
Expiration Date: January 31, 2017 |
|-------------------------------------------------------------------------|-----------------------------------------------------------------------|
| Indications for Use | See PRA Statement below. |
| 510(k) Number ( if known ) | K172372 |
|---|---|
| Device Name | QuadraSphere Microspheres |
| Indications for Use ( Describe ) | QuadraSphere Microspheres are indicated for embolization of hypervascularized tumors including hepatoma, and peripheral arteriovenous malformations. |
| Type of Use ( Select one or both, as applicable ) | |
|---|---|
| Prescription Use (Part 21 CFR 801 Subpart D) | Over-The-Counter Use (21 CFR 801 Subpart C) |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services
Food and Drug Administration
Office of Chief Information Officer
Paperwork Reduction Act (PRA) Staff
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
FORM FDA 3881 (8/14)
PSC Publishing Services (301) 443-6740
3
| August 02, 2017 | ||
|---|---|---|
| General | ||
| Provisions | Submitter Name: | |
| Address: | ||
| Telephone Number: | ||
| Fax Number: | ||
| Contact Person: | ||
| Registration Number: | Biosphere Medical, S.A. | |
| Parc des Nations – Paris Nord 2 | ||
| 383, rue de la Belle Etoile | ||
| 95700 Roissy-en-France, France | ||
| +33 (0)1 48 17 25 29 | ||
| +33 (0)1 49 38 02 68 | ||
| Alix Fonlladosa | ||
| 9615728 | ||
| Correspondent Name: | ||
| Address: | ||
| Telephone Number: | ||
| Fax Number: | ||
| Contact Person: | ||
| Registration Number: | Biosphere Medical, S.A. | |
| Parc des Nations – Paris Nord 2 | ||
| 383, rue de la Belle Etoile | ||
| 95700 Roissy-en-France, France | ||
| +33 (0)1 48 17 25 21 | ||
| +33 (0)1 49 38 02 68 | ||
| Lionel Ekedi Ngando | ||
| 9615728 | ||
| Subject | ||
| Device | Trade Name: | |
| Common/Usual Name: | ||
| Classification Name: | QuadraSphere® Microspheres | |
| Embolization Device | ||
| 21 CFR 870.3300 Vascular Embolization Device | ||
| 21 CFR 882.5950 Neurovascular Embolization Device | ||
| Predicate Device | Trade Name: | |
| Common/Usual Name: | ||
| Classification Name: | ||
| Manufacturer: | ||
| Premarket Notification: | QuadraSphere® Microspheres | |
| Embolization Device | ||
| 21 CFR 870.3300 Vascular Embolization Device | ||
| 21 CFR 882.5950 Neurovascular Embolization Device | ||
| Biosphere Medical, S.A. | ||
| K153102, cleared November 23, 2015 | ||
| Classification | Class II | |
| 21 CFR 870.3300 | ||
| 21 CFR 882.5950 | ||
| FDA Product Code: | KRD and HCG | |
| Review Panel: Division of Cardiovascular Devices |
4
QuadraSphere Microspheres are indicated for embolization of Intended Use hypervascularized tumors including hepatoma, and peripheral arteriovenous malformations.
QuadraSphere Microspheres are sterile, biocompatible, hydrophilic, nonresorbable, expandable, acrylic copolymer microspheres. QuadraSphere Microspheres are packaged in a vial containing 25 mg of dry microspheres. The expansion rate is dependent on ionic concentration. When in contact with blood, non-ionic contrast media, or normal saline (NaCl 0.9%), QuadraSphere Microspheres expand to approximately 4 times their dry state diameter; equal to 64x volume.
They are available in a range of sizes.
| Reference | Size range (µm) |
|---|---|
| V125QS | 20-40 |
| V225QS | 30-60 |
| V325QS | 50-100 |
| V525QS | 100-150 |
| V725QS | 150-200 |
QuadraSphere Microspheres have the following properties:
Device Description
- Spherical shape with consistent cross sectional diameter after ● reconstitution with aqueous-based solutions such as contrast media and 0.9% saline solution for predictable flow directed level of occlusion in the vasculature.
- Rapidly absorb contrast media and 0.9% saline solution.
- . Conform to vessel lumen, providing more surface contact with vessel intima.
- Expand up to four times the stated dry diameter when hydrated with . non-ionic aqueous solutions, resulting in an increase in surface area contact for a more complete vessel occlusion.
The principles of operation for the QuadraSphere Microspheres are the same as the predicate device K153102. QuadraSphere Microspheres are permanent implantable devices and are designed for controlled, targeted embolization. The device is provided dry (in a vial) and must be rehydrated before use. The microspheres are injected into the target vessel with an intravascular catheter(s) to selectively occlude blood vessels. Contrast enhancement using commercially available ionic or non-ionic contrast media allows the embolization procedure to be monitored using fluoroscopy. The embolization agents are intended for single use and are provided sterile.
5
The technological characteristics of the subject of this Special 510(k) are substantially equivalent to the predicate QuadraSphere Microspheres, K153102 cleared on November 23, 2015. Both devices use the same components and materials. The device indications remain unchanged.
| Technological Characteristics Comparison Table | |||
|---|---|---|---|
| Bold type indicates differences between subject and predicate device, K1513102. | |||
| Attribute | Predicate | ||
| Device | |||
| QuadraSphere | |||
| Microspheres | |||
| K153102 | Subject Device | ||
| QuadraSphere | |||
| Microspheres | |||
| 20-40μm | Comment | ||
| Microspheres Size | 30 to 60μm, | ||
| 50 to 100μm, | |||
| 100 to 150μm, | |||
| 150 to 200μm | 20 to 40 μm | ||
| 30 to 60μm, | |||
| 50 to 100μm, | |||
| 100 to 150μm, | |||
| 150 to 200μm | Will be extended | ||
| to 20-40μm | |||
| Catheter | |||
| compatibility | |||
| Comparison to | |||
| Predicate | 20 to 40µm - ≥ 0.020" | ||
| 30 to 60µm - ≥ 0.021" | |||
| 50 to 100µm - ≥0.021" | |||
| 100 to 150µm - ≥ 0.024" | |||
| 150 to 200µm - ≥ 0.027" | Injectable in | ||
| 0.020" and wider | |||
| ID microcatheters. | |||
| Shelf Life | |||
| (Single use) | Three years | ||
| (36 months) | Three years | ||
| (36months) | Same | ||
| Material (spheres) | PVA Acrylic | ||
| Copolymer (vinyl | |||
| alcohol-sodium | |||
| acrylate) | PVA Acrylic | ||
| Copolymer (vinyl | |||
| alcohol-sodium | |||
| acrylate) | Sa me | ||
| Physical | |||
| Characteristics | Biocompatible, | ||
| hydrophilic, non- | |||
| resorbable, | |||
| expandable, | |||
| conformable and | |||
| swell upon | |||
| exposure to | |||
| aqueous | |||
| solutions | Biocompatible, | ||
| hydrophilic, non- | |||
| resorbable, | |||
| expandable, | |||
| conformable and | |||
| swell upon | |||
| exposure to | |||
| aqueous | |||
| solutions | Same | ||
| Principle of | |||
| Operation | The microspheres | ||
| are administered | |||
| with radiopaque | |||
| contrast medium | |||
| into the patient's | |||
| artery via a | |||
| microcatheter. | The microspheres | ||
| are administered | |||
| with radiopaque | |||
| contrast medium | |||
| into the patient's | |||
| artery via a | |||
| microcatheter. | Same principle of | ||
| operation | |||
| Sterilization | Radiation | ||
| Sterilized | Radiation | ||
| Sterilized | Same | ||
| Performance | Designed for | ||
| controlled, | |||
| targeted | |||
| embolization | |||
| when vessel | |||
| conformity is | |||
| desired | Designed for | ||
| controlled, | |||
| targeted | |||
| embolization | |||
| when vessel | |||
| conformity is | |||
| desired | Same | ||
| Volume of | |||
| Microspheres in | |||
| Vial (dry) | 25 mg per vial | 25 mg per vial | Same |
6
BioSphere Medical, S.A. bases its claim of the substantial equivalence of the QuadraSphere Microspheres with the cited predicate device based on intended use, indic ntal scientific technological characteristics, and fundamental operational characteristics. In all cases, the embolization agent is delivered to selected sites through catheters with a diameter that is appropriate for the vascular target and the size of the embolization agent. Accurate placement is assured through visualization of the injection process using fluoroscopic imaging. Embolization agents are mixed with the contrast media before injection to optimize visualization of the embolization procedure. The subject device, QuadraSphere® Microspheres, is available in a 20 to 40 um size microspheres to permit selection of the appropriate size for target vessels. All cited embolization agents are intended for single use and are provided sterile.
Safety & Performance Tests
No performance standards applicable to this device have been adopted under Section 514 of the Act. However, vascular embolization devices are subject to the special controls specified in "Guidance for Industry and FDA Staff - Class II Special Controls Guidance Document: Vascular and Neurovascular Embolization Devices," issued on December 29, 2004.
Biocompatibility assessment was performed in accordance with ISO 10993-1 for permanent implants in contact with blood for the predicate device and are being adopted for this subject device based upon the fact that both devices are made from the same materials using the same processes with now the inclusion of an additional size offering.
In-vitro and in-vivo (animal study) design verification and validation testing demonstrates that the BioSphere Medical QuadraSphere Microspheres 20 to 40µm fulfill design and performance specifications. Performance testing of the subject device was conducted based on the requirements of design input and output requirements as below:
- Macroscopic appearance of the powder .
- Microscopic examination of the microspheres ●
- Swelling in Hexabrix of the microspheres .
- Humidity of the microspheres
7
| Bacterial endotoxins Catheter compatibility Animal testing | |
|---|---|
| The results of the testing demonstrated that the subject BioSphere Medical | |
| QuadraSphere Microspheres 20 to 40 µm met the pre-determined | |
| acceptance criteria applicable to the size requirements and performance of | |
| the device. | |
| Summary of | |
| Substantial | |
| Equivalence | Based on the same intended use, design, fundamental scientific |
| technological characteristics, fundamental operational characteristics and | |
| safety and performance testing, the BioSphere Medical subject | |
| QuadraSphere Microspheres 20 to 40 µm device meets the requirements | |
| that are considered essential for its intended use and is substantially | |
| equivalent to the predicate device, QuadraSphere Microspheres K153102. |